---
layout: default
title: Acetaldehyde Acetone Amaryllis Belladonna Whole Be
parent: 僅模型預測 (L5)
nav_order: 84
evidence_level: L5
indication_count: 0
---

# Acetaldehyde Acetone Amaryllis Belladonna Whole Be
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Mixture (15 Ingredients): No Repurposing Prediction Available

## One-Sentence Summary

This submission contains a complex 15-component mixture including several inherently toxic substances (e.g., benzene, strychnos nux-vomica seed, colchicum autumnale bulb, phosphorus). The TxGNN model returned **no predicted new indications** for this combination, and the mixture holds **no regulatory approval** in any queried jurisdiction. Given the complete absence of predictions and pervasive data gaps, this candidate **cannot be evaluated** under the standard repurposing framework.

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Unknown — no regulatory records found |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

## Why is This Prediction Reasonable?

No TxGNN prediction is available for this candidate; therefore, a mechanistic rationale for repurposing cannot be constructed.

The 15 listed components span radically different chemical classes: industrial solvents and reactive species (acetaldehyde, acetone, benzene), plant-derived alkaloid sources (strychnos nux-vomica seed, colchicum autumnale bulb, schoenocaulon officinale seed, amaryllis belladonna whole), aromatic/essential oil constituents (eugenol, cananga odorata leaf oil, citrus aurantium flower oil, cinnamic acid), a functional phytochemical (indole-3-carbinol), and inorganic/mineral substances (phosphorus, sulfur iodide, liquid petroleum). Several of these are acutely toxic or regulated as hazardous materials in most jurisdictions.

Without a coherent shared pharmacological mechanism, no disease-indication link can be proposed and no repurposing hypothesis can be evaluated at this stage.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## US Market Information

This mixture holds no US FDA-approved product records and is not marketed. No license table can be generated.

## Safety Considerations

Several components of this mixture carry well-documented toxicity profiles that warrant immediate attention:

- **BENZENE**: IARC Group 1 human carcinogen; causes aplastic anemia, acute myeloid leukemia, and chromosomal damage with chronic exposure.
- **STRYCHNOS NUX-VOMICA SEED**: Contains strychnine and brucine — potent competitive glycine antagonists; extremely narrow therapeutic index, high fatality risk in overdose.
- **COLCHICUM AUTUMNALE BULB**: Source of colchicine; associated with severe gastrointestinal toxicity, bone marrow suppression, and multi-organ failure in overdose.
- **SCHOENOCAULON OFFICINALE SEED**: Contains veratrum alkaloids (cevadine, veratridine); cardiovascular collapse and neurotoxicity risks.
- **PHOSPHORUS**: Systemic hepatotoxin and nephrotoxin at low doses; burns tissue on contact.
- **LIQUID PETROLEUM**: Not intended for internal therapeutic use; significant aspiration pneumonia risk.
- **SULFUR IODIDE**: Corrosive and reactive; formal therapeutic safety data is absent.

Formal drug–drug interaction data and structured contraindication records are not available in queried databases for this multi-ingredient combination.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate returns no TxGNN repurposing predictions and carries zero regulatory approval in any queried jurisdiction. Multiple components are classified as known toxins, carcinogens, or hazardous substances, making a favorable benefit–risk profile implausible without extraordinary evidence and a clearly defined therapeutic context.

**To proceed, the following is needed:**
- Clarify the intended product category: homeopathic preparation, traditional medicine, industrial compound, or research mixture — as each follows a different regulatory and evaluation pathway
- Provide dosage form and per-ingredient concentration data, since toxicological risk is heavily concentration-dependent (e.g., colchicine at homeopathic dilution vs. pharmacological dose)
- Commission a formal toxicology review given the presence of benzene, strychnine-containing seeds, colchicum alkaloids, and elemental phosphorus
- If a legitimate therapeutic claim exists, retrieve the full package insert, historical indication records, and MOA data from the originating regulatory authority
- Re-submit individual active ingredient INN codes (rather than the full concatenated string) to the TxGNN pipeline to obtain component-level repurposing predictions
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

